ReviewFrontiers in pharmacology2022
Apoptosis Induction, a Sharp Edge of Berberine to Exert Anti-Cancer Effects, Focus on Breast, Lung, and Liver Cancer.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 56 citations in OpenAlex.
- Room-Temperature Synthesis of Anionic Covalent Organic Framework Monolithic Materials for Efficient Capturing of Berberine Hydrochloride.Journal of separation science · 2026Article
- Article
- Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Review
- Cellular and Molecular Mechanisms of Berberine in Cancer Therapy: Recent Advances.Archiv der Pharmazie · 2026Review
- Natural Products Targeting Key Molecular Hallmarks in Gastric Cancer: Focus on Apoptosis, Inflammation, and Chemoresistance.International journal of molecular sciences · 2026Review
- Correlative study ofFrontiers in microbiology · 2026Article
- Multi-omics integration and experimental validation reveal the mechanism of berberine against triple-negative breast cancer.Frontiers in pharmacology · 2026Article
- Current Therapeutic Strategies, Recent Advances and the Emerging Potential of Natural Products in Hepatocellular Carcinoma.Scientifica · 2026Review
- Synthesis and anti-cancer biological evaluation of a novel protoapigenone analogue, WYC-241.RSC medicinal chemistry · 2025Article
- Roles of Selected Bioactive Compounds in Inhibiting the Development and Progression of Cancer-A Review.International journal of molecular sciences · 2025Review
- Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating Oncological Disorders.Phytotherapy research : PTR · 2025Review
- Berberine and its impact on breast cancer: unveiling key signalling pathways.Molecular biology reports · 2025Review
- Berberine's Impact on Apoptosis, Proliferation, Uptake Efficiency, and Nanoparticle-Based Therapy in DBTRG Cells.ACS nanoscience Au · 2025Article
- Chemical composition, antioxidant, antimicrobial, and anticancer activities of Mahonia napaulensis DC. bark from Nepal.BMC complementary medicine and therapies · 2025Article
- Enhancing the Therapeutic Efficacy of Berberine and Quercetin Through Salt Formulation for Liver Fibrosis Treatment.International journal of molecular sciences · 2025Article
- Molecular dynamics and experimental evaluation of piperine as a potential mTOR inhibitor in colon cancer cells.In silico pharmacology · 2025Article
- Article
- A Novel Delivery System for the Combined Use of Natural Ingredients: The Preparation of Berberine Hydrochloride-Matrine Liposomes and Preliminary Exploration of Their Anti-Tumor Activity.Molecules (Basel, Switzerland) · 2024Article
- Harnessing the nutriceutics in early-stage breast cancer: mechanisms, combinational therapy, and drug delivery.Journal of nanobiotechnology · 2024Review
- Natural Compounds for Preventing Age-Related Diseases and Cancers.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the leading cause of death and one of the greatest barriers to increased life expectancy worldwide. Currently, chemotherapy with synthetic drugs remains one of the predominant ways for cancer treatment, which may lead to drug resistance and normal organ damage. Increasing researches have suggested that apoptosis, a type of programmed cell death, is a promising way for cancer therapy. Furthermore, natural products are important sources for finding new drugs with high availability, low cost and low toxicity. As a well-known isoquinoline alkaloid, accumulating evidence has revealed that berberine (BBR) exerts potential pro-apoptotic effects on multiple cancers, including breast, lung, liver, gastric, colorectal, pancreatic, and ovarian cancers. The related potential signal pathways are AMP-activated protein kinase, mitogen-activated protein kinase, and protein kinase B pathways. In this review, we provide a timely and comprehensive summary of the detailed molecular mechanisms of BBR in treating three types of cancer (breast, lung and liver cancer) by inducing apoptosis. Furthermore, we also discuss the existing challenges and strategies to improve BBR's bioavailability. Hopefully, this review provides valuable information for the comprehension of BBR in treating three types of cancer and highlight the pro-apoptotic effects of BBR, which would be beneficial for the further development of this natural compound as an effective clinical drug for treating cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.